New Key Statistics Module, Z-Score and F-Score
AMEX:NBY Key Ratios
| Market Cap $ M | 3.71 |
| Enterprise Value $ M | 5.22 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 0.02 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 12.00 |
| EPS (TTM) $ | -48.15 |
| Beneish M-Score | -6.3 |
| 10-y EBITDA Growth Rate % | 42.40 |
| 5-y EBITDA Growth Rate % | 37.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.89 |
| EV-to-EBITDA | -0.93 |
| PEG | -- |
| Shares Outstanding M | 4.89 |
| Net Margin (%) | -88.70 |
| Operating Margin % | -37.74 |
| Pre-tax Margin (%) | -87.67 |
| Quick Ratio | 0.43 |
| Current Ratio | 0.62 |
| ROA % (ttm) | -113.02 |
| ROE % (ttm) | -288.89 |
| ROIC % (ttm) | -78.75 |
| Dividend Yield % | -- |
| Altman Z-Score | -69.31 |
NBY Number of Guru Trades
NBY Volume of Guru Trades
Gurus Latest Trades with AMEX:NBY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
AMEX:NBY is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NovaBay Pharmaceuticals Inc Insider Transactions
No Available Data
News about AMEX:NBY
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers